What is Gritstone Bio?
Gritstone Bio is a clinical-stage biotechnology enterprise dedicated to the development of groundbreaking immunotherapies. The company specializes in the identification and utilization of antigens to create potent vaccines and therapeutic interventions for cancers and infectious diseases. By leveraging advanced molecular insights, Gritstone Bio aims to address significant unmet medical needs, operating at the intersection of immunology and synthetic biology. Its market position is defined by a commitment to scientific rigor and the translation of complex biological data into viable clinical candidates, supported by a sophisticated ecosystem of life science investors.
How much funding has Gritstone Bio raised?
Gritstone Bio has raised a total of $472.1M across 5 funding rounds:
Series A
$102M
Series B
$92.7M
Stock Offering
$92.6M
Stock Offering
$74.8M
Share Placement
$110M
Series A (2015): $102M with participation from Clarus Ventures, Transformational Healthcare Opportunity, Redmile Group, Frazier Healthcare Partners, Versant Ventures, The Column Group, and Casdin Capital
Series B (2017): $92.7M led by GV, Clarus Funds, Frazier Healthcare Partners, Trinitas Capital Management, Alexandria Venture Investments, Versant Ventures, The Column Group, and Lilly Asia Ventures
Stock Issuance/Offering (2018): $92.6M supported by Undisclosed
Stock Issuance/Offering (2019): $74.8M featuring Undisclosed
Share Placement (2020): $110M backed by Redmile Group, EcoR1 Capital, and Avidity Partners
Key Investors in Gritstone Bio
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world, leveraging extensive backgrounds in venture capital and pharmaceuticals.
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, utilizing an edge-to-edge investment model to nurture therapeutic breakthroughs.
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, dedicated to advancing therapeutic innovation and developing new medicines through long-term partnerships.
What's next for Gritstone Bio?
Looking ahead, Gritstone Bio is poised to leverage its recent capital infusion to advance its lead clinical programs and expand its technological infrastructure. The strategic focus remains on validating its immunotherapy platforms through rigorous clinical trials and potential commercialization pathways. As the company matures, the emphasis will likely shift toward scaling manufacturing capabilities and deepening its research into novel antigen targets. With a strong foundation of institutional support, Gritstone Bio is well-positioned to navigate the competitive biotechnology sector, aiming to deliver transformative health outcomes while maintaining its trajectory of innovation and operational excellence.
See full Gritstone Bio company page
